Tuberculosis (TB) suspect is any one who has signs or symptoms suggestive of TB (eg >2 weeks productive cough).
Definite TB is considered in patients with culture or molecular line probe assay positive for Mycobacterium tuberculosis, or in patients with at least 1 sputum smear positive for acid-fast bacilli.
TB cases are also classified based on the disease anatomical site, bacteriological results (including drug resistance), previous treatment history and patient's HIV status.
Pulmonary TB is a case of TB that involves the lung parenchyma.
Miliary TB is considered as PTB since lung lesions are also seen.
TB in the pleural effusion, mediastinal and/or hilar lymph nodes with no evidence of abnormalities in the chest x-ray are considered extrapulmonary TB.
Patients presenting with both PTB and extrapulmonary TB are classified as a case of PTB.
Individuals who have undergone gastrectomy for stomach cancer may have an added risk of developing tuberculosis (TB), according to a study from South Korea. However, this elevated risk does not appear to extend to nontuberculous mycobacteria (NTM) lung disease.
Having a high initial effusion volume of >1,000 cc was associated with an increased need for surgical intervention after treatment with chest tube thoracostomy (CTT) in patients with loculated pleural effusion, according to a study presented at the APSR 2017 Congress.
Metformin may improve survival during tuberculosis (TB) treatment in patients with diabetes mellitus—a condition which particularly carries an increased risk of adverse TB treatment outcomes, a study has found.
Statins appear to have a dose-dependent association with the risk of tuberculosis (TB), with a nationwide population-based study showing that statin users have 47 percent lower incidence of TB compared with nonusers.
Patients treated with tumour necrosis factor (TNF)-α antagonists may be at a greater risk of tuberculosis (TB), although the biological mechanism underlying this association needs to be elucidated, according to a meta-analysis.
Lowering the dosage of aminoglycosides guided by therapeutic dose monitoring (TDM) may reduce aminoglycoside-related hearing loss, without compromising its efficacy against multidrug resistant tuberculosis (MDR-TB), a recent study suggests.
The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.